GPC Biotech AG (NASDAQ: GPCB), a biopharmaceutical company, is focused on discovering, developing, and commercializing anticancer drugs. Its pipeline of products include satraplatin, an oral platinum-based anticancer agent that is in phase 1 and 2 trials; RGB-286638, a broad-spectrum kinase inhibitor that has completed pre-clinical testing; and RGB-344064, a selective inhibitor of cyclin-dependent kinases that is in pre-clinical testing. For further information, visit the Company’s web site at www.gpc-biotech.com.
- 18 years ago
QualityStocks
GPC Biotech AG (NASDAQ: GPCB)
Tags Rodman & Renshaw
Related Post
-
Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
In the United States alone, close to one million people are living with MS, with…
-
Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step
California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…
-
Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership
The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…